On June 12, 2014 TeraDiscoveries, Inc., a bio-therapeutics company focused on cloud-based drug design and development, reported that effective immediately, it has changed its corporate name to Cloud Pharmaceuticals, Inc (Press release, TeraDiscoveries, JUN 12, 2014, View Source [SID1234635437]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cloud Pharmaceuticals designs new drugs and drug candidates and accelerates the development process by implementing new, innovative cloud computing technology in place of traditional methods. The company manages the development of multiple drug candidates through an extensive network of partners.
"The worldwide pharmaceutical industry is in need of new drugs that target smaller market segments. They need to be developed faster, have novel IP, and offer greater drug safety, efficacy, and affordability," says Ed Addison, company president and CEO. "Our approach uses cloud technology and high-performance computing to efficiently calculate which of all possible molecules are the best drug candidates. This reduces cost, decreases development time, and creates novel molecules with therapeutic value. Our new name more aptly reflects our approach and value proposition."
Cloud Pharmaceuticals is helping to transform the pharmaceutical and biotechnology industries to enable personalized medicine, niche buster drugs, and rapidly developed blockbusters for difficult targets. The company uses a method originally developed at Duke University called Inverse Design to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.